Trial design for assessing analytical and clinical performance of high-sensitivity cardiac troponin I assays in the United States: The HIGH-US study

Contemporary Clinical Trials Communications

Volumn 14, Issue , 2019, Pages

  Christenson, R H ^a   Peacock, W F ^b   Apple, F S ^c   Limkakeng, A T ^d   Nowak, R M ^e   McCord, J ^f   deFilippi, C R ^g  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

^f HENRY FORD HOSPITAL   (United States)

^g INOVA HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

99th percentile; Analytical characteristics; Clinical performance; High sensitivity cardiac troponin; Immunoassay; Sex specific 99th percentile cutoffs

Indexed keywords

BILIRUBIN; BILIRUBIN GLUCURONIDE; BIOTIN; CHOLESTEROL; HEMOGLOBIN; TRIACYLGLYCEROL; TROPONIN I;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CARDIOLOGIST; CHOLESTEROL BLOOD LEVEL; DIAGNOSTIC ACCURACY; EMERGENCY MEDICINE; FEMALE; FOOD AND DRUG ADMINISTRATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOASSAY; ISCHEMIC HEART DISEASE; LIMIT OF BLANK; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; NORMAL HUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; STUDY DESIGN; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

EID: 85061806373     PISSN: 24518654     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.conctc.2019.100337     Document Type: Article

References (45)

1. Benjamin, E.J., Virani, S.S., Callaway, C.W., Chamberlain, A.M., Chang, A.R., Cheng, S., et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 137 (2018), e67–e492 https://doi.org/10.1161/cir.0000000000000558.
2. Thygesen, K., Alpert, J.S., Jaffe, A.S., Chaitman, B.R., Bax, J.J., Morrow, D.A., et al. Fourth universal definition of myocardial infarction (2018). J. Am. Coll. Cardiol., 72, 2018, 2231 https://doi.org/10.1016/j.jacc.2018.08.1038.
3. Antman, E.M., Tanasijevic, M.J., Thompson, B., Schactman, M., McCabe, C.H., Cannon, C.P., et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N. Engl. J. Med. 335 (1996), 1342–1349 https://doi.org/10.1056/nejm199610313351802.
4. Bertinchant, J.P., Larue, C., Pernel, I., Ledermann, B., Fabbro-Peray, P., Beck, L., et al. Release kinetics of serum cardiac troponin I in ischemic myocardial injury. Clin. Biochem. 29 (1996), 587–594.
5. Ravkilde, J., Nissen, H., Horder, M., Thygesen, K., Independent prognostic value of serum creatine kinase isoenzyme MB mass, cardiac troponin T and myosin light chain levels in suspected acute myocardial infarction. Analysis of 28 months of follow-up in 196 patients. J. Am. Coll. Cardiol. 25 (1995), 574–581 https://doi.org/10.1016/0735-1097(94)00430-x.
6. Wu, A.H., Lane, P.L., Metaanalysis in clinical chemistry: validation of cardiac troponin T as a marker for ischemic heart diseases. Clin. Chem. 41 (1995), 1228–1233.
7. Wu, A.H.B., Christenson, R.H., Greene, D.N., Jaffe, A.S., Kavsak, P.A., Ordonez-Llanos, J., et al. Clinical laboratory practice recommendations for the use of cardiac troponin in acute coronary syndrome: Expert opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clin. Chem. 64 (2018), 645–655 https://doi.org/10.1373/clinchem.2017.277186.
8. Amsterdam, E.A., Wenger, N.K., Brindis, R.G., Casey, D.E. Jr., Ganiats, T.G., Holmes, D.R. Jr., et al. AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 130 (2014), e344–426 2014 https://doi.org/10.1161/CIR.0000000000000134.
9. Apple, F.S., Jaffe, A.S., Collinson, P., Mockel, M., Ordonez-Llanos, J., Lindahl, B., et al. IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays. Clin. Biochem. 48 (2015), 201–203 https://doi.org/10.1016/j.clinbiochem.2014.08.021.
10. Thygesen, K., Alpert, J.S., Jaffe, A.S., Simoons, M.L., Chaitman, B.R., White, H.D., et al. Third universal definition of myocardial infarction. Circulation 126 (2012), 2020–2035 https://doi.org/10.1161/CIR.0b013e31826e1058.
11. Thygesen, K., Mair, J., Giannitsis, E., Mueller, C., Lindahl, B., Blankenberg, S., et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur. Heart J. 33 (2012), 2252–2257 https://doi.org/10.1093/eurheartj/ehs154.
12. Clinical and Laboratory Standards Institute. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. third ed., 2010, Clinical and Laboratory Standards Institute, Wayne, PA CLSI Document EP28-A3c.
13. High-Sensitivity* Cardiac Troponin I and T Assay Analytical Characteristics Designated by Manufacturer IFCC Committee on Clinical Applications of Cardiac Bio-Markers (C-CB) v082318, 2018 http://www.ifcc.org/media/477441/high-sensitivity-cardiac-troponin-i-and-t-assay-analytical-characteristics-designated-by-manufacturer-v08232018.pdf. (Accessed 4 December 2018)
14. Natrajan, A., Wen, D., A comparison of chemiluminescent acridinium dimethylphenyl ester labels with different conjugation sites. Org. Biomol. Chem. 13 (2015), 2622–2633 https://doi.org/10.1039/c4ob02528h.
15. Siemens Healthcare Diagnostics. ADVIA Centaur® XP, ADVIA Centaur® XPT High-Sensitivity Troponin I (TNIH) Assay instructions for use. 11200076_EN, rev. A. 2017 Mar, Siemens, Tarrytown (NY).
16. ® IM High-Sensitivity Troponin I (TnIH) assay instructions for use, OUS. 11200497_EN Rev. 03 Tarrytown (NY). 2018 July, Siemens.
17. ® High-Sensitivity Troponin I (TNIH) assay instructions for use. PN 10866031, rev D. 2017 Oct, Siemens, Tarrytown (NY).
18. ® High Sensitivity Troponin I (TNIH) assay instructions for use. PN 10868015, rev D. 2017 Oct, Siemens, Tarrytown (NY).
19. Clinical and Laboratory Standards Institute. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline. second ed., 2012, Clinical and Laboratory Standards Institute, Wayne, PA CLSI document EP17-A2.
20. Clinical and Laboratory Standards Institute. Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline. third ed., 2014, Clinical and Laboratory Standards Institute, Wayne, PA CLSI Document EP05-A3.
21. Clinical and Laboratory Standards Institute. Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved guideline. third ed., 2013, Clinical and Laboratory Standards Institute, Wayne, PA CLSI Document EP09-A3.
22. Clinical and Laboratory Standards Institute. Interference Testing in Clinical Chemistry; Approved Guideline. second ed., 2005, Clinical and Laboratory Standards Institute, Wayne, PA CLSI document EP07-A2.
23. Clinical and Laboratory Standards Institute. User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline. second ed., 2008, Clinical and Laboratory Standards Institute, Wayne, PA CLSI document EP12-A2.
24. Wu, A.H.B., Apple, F., Love, S.A., Koch, D., Myers, G.L., Christenson, R.H., Creation of a universal sample bank for determining the 99th percentile for cardiac troponin assays. J Appl Lab Med 1 (2017), 711–719.
25. Levin, A., Stevens, P.E., Co-chairs: Kidney Disease: Improving Global Outcomes Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl., 3, 2013 v-150 https://doi.org/doi:10.1038/kisup.2012.74.
26. Wilson, E.B., Probable inference, the law of succession, and statistical inference. J. Am. Stat. Assoc. 22 (1927), 209–212 https://doi.org/10.1080/01621459.1927.10502953. JSTOR 2276774.
27. Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Blaha, M.J., et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 129 (2014), e28–e292 https://doi.org/10.1161/01.cir.0000441139.02102.80.
28. Tomaszewski, C.A., Nestler, D., Shah, K.H., Sudhir, A., Brown, M.D., Clinical Policy: Critical issues in the evaluation and management of emergency department patients with suspected Non-ST-elevation acute coronary syndromes. Ann. Emerg. Med. 72 (2018), e65–e106 https://doi.org/10.1016/j.annemergmed.2018.07.045.
29. Anderson, J.L., Adams, C.D., Antman, E.M., Bridges, C.R., Califf, R.M., Casey, D.E. Jr., et al. ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 61 (2012), e179–347 2013 https://doi.org/10.1016/j.jacc.2013.01.014.
30. Forberg, J.L., Henriksen, L.S., Edenbrandt, L., Ekelund, U., Direct hospital costs of chest pain patients attending the emergency department: a retrospective study. BMC Emerg. Med., 6, 2006, 6 https://doi.org/10.1186/1471-227x-6-6.
31. Hamm, C.W., Bassand, J.P., Agewall, S., Bax, J., Boersma, E., Bueno, H., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32 (2011), 2999–3054 https://doi.org/10.1093/eurheartj/ehr236.
32. Roffi, M., Patrono, C., Collet, J.P., Mueller, C., Valgimigli, M., Andreotti, F., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur. Heart J. 37 (2015), 267–315 2016 https://doi.org/10.1093/eurheartj/ehv320.
33. Than, M.P., Pickering, J.W., Dryden, J.M., Lord, S.J., Aitken, S.A., Aldous, S.J., et al. ICare-ACS (Improving Care Processes for Patients With Suspected Acute Coronary Syndrome): a study of cross-system implementation of a national clinical pathway. Circulation 137 (2018), 354–363 https://doi.org/10.1161/circulationaha.117.031984.
34. Sandoval, Y., Smith, S.W., Love, S.A., Sexter, A., Schulz, K., Apple, F.S., Single high-sensitivity cardiac troponin I to rule out acute myocardial infarction. Am. J. Med. 130 (2017), 1076–1083 e1 https://doi.org/10.1016/j.amjmed.2017.02.032.
35. Apple, F.S., Sandoval, Y., Jaffe, A.S., Ordonez-Llanos, J., Cardiac troponin assays: Guide to understanding analytical characteristics and their impact on clinical care. Clin. Chem. 63 (2017), 73–81 https://doi.org/10.1373/clinchem.2016.255109.
36. Gunsolus, I., Sandoval, Y., Smith, S.W., Sexter, A., Schulz, K., Herzog, C.A., et al. Renal dysfunction influences the diagnostic and prognostic performance of high-sensitivity cardiac troponin I. J. Am. Soc. Nephrol. 29 (2018), 636–643 https://doi.org/10.1681/asn.2017030341.
37. Chapman, A.R., Lee, K.K., McAllister, D.A., Cullen, L., Greenslade, J.H., Parsonage, W., et al. Association of high-sensitivity cardiac troponin I concentration with cardiac outcomes in patients with suspected acute coronary syndrome. J. Am. Med. Assoc. 318 (2017), 1913–1924 https://doi.org/10.1001/jama.2017.17488.
38. Christenson, R.H., Mullins, K., Duh, S.H., Validation of high-sensitivity performance for a United States Food and Drug Administration cleared cardiac troponin I assay. Clin. Biochem. 56 (2018), 4–10 https://doi.org/10.1016/j.clinbiochem.2018.05.004.
39. McCord, J., Newby, L.K., deFilippi, C.R., Designing a better mousetrap: reflections on the November 28, 2017, US food and drug administration meeting on next-generation “High-Sensitivity” cardiac troponin assays to diagnose myocardial infarction. Circulation 138 (2018), 316–318 https://doi.org/10.1161/circulationaha.118.033955.
40. Nowak, R.M., Gandolfo, C.M., Jacobsen, G., Christenson, R.H., Moyer, M., Hudson, M., et al. Ultrarapid rule-out for acute myocardial infarction using the generation 5 cardiac troponin T assay: results from the REACTION-US study. Ann. Emerg. Med. 72 (2018), 654–664 https://doi.org/10.1016/j.annemergmed.2018.06.021.
41. Nowak, R.M., Gandolfo, C.M., Jacobsen, G., Christenson, R.H., Moyer, M., Hudson, M., et al. 1-h evaluation for acute myocardial infarction using the generation 5 cardiac troponin T assay. J. Am. Coll. Cardiol. 72 (2018), 2677–2679 https://doi.org/10.1016/j.jacc.2018.08.2190.
42. Peacock, W.F., Baumann, B.M., Bruton, D., Davis, T.E., Handy, B., Jones, C.W., et al. Efficacy of high-sensitivity troponin T in identifying very-low-risk patients with possible acute coronary syndrome. JAMA cardiology 3 (2018), 104–111 https://doi.org/10.1001/jamacardio.2017.4625.
43. Shah, A.S.V., Sandoval, Y., Noaman, A., Sexter, A., Vaswani, A., Smith, S.W., et al. Patient selection for high sensitivity cardiac troponin testing and diagnosis of myocardial infarction: prospective cohort study. BMJ, 359, 2017, j4788 https://doi.org/10.1136/bmj.j4788.
44. Sandoval, Y., Smith, S.W., Thordsen, S.E., Bruen, C.A., Carlson, M.D., Dodd, K.W., et al. Diagnostic performance of high sensitivity compared with contemporary cardiac troponin I for the diagnosis of acute myocardial infarction. Clin. Chem. 63 (2017), 1594–1604 https://doi.org/10.1373/clinchem.2017.272930.
45. Ford, F., Shah, A.S.V., Zhang, R., McAllister, D.A., Strachan, F.E., Caslake, M., et al. High-Sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J. Am. Coll. Cardiol. 68 (2016), 2719–2728 https://doi.org/https://doi.org/10.1016/j.jacc.2016.10.020.